• In June 2026, Ulta Beauty expanded its assortment by adding wellness brand Being Frenshe to stores nationwide and online, while also launching Ayesha Curry’s Sweet July Skin products on Ulta.com alongside reporting strong first-quarter fiscal 2026 results with higher net sales, comparable sales, operating income, and earnings per share.
• These launches underscore Ulta’s emphasis on wellness-driven beauty and exclusive brand partnerships, reinforcing the importance of its broad assortment and loyalty ecosystem in attracting trend-conscious consumers.
• Building on this wellness-focused brand expansion, we’ll explore how Ulta’s new partnerships with Being Frenshe and Sweet July Skin influence its investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.

Ulta Beauty Investment Narrative Recap

To own Ulta Beauty, you need to believe its broad assortment, powerful loyalty program, and wellness expansion can support profitable growth despite rising costs and intense competition. The latest wellness launches look directionally positive, but they do not materially change the near term focus on offsetting higher labor and store expenses or the looming loss of the Target partnership, which remains a key risk to earnings quality.

Among the recent developments, the launch of Being Frenshe across Ulta stores and online best ties into the core wellness catalyst. It strengthens Ulta’s position in self care and mood based beauty, supports the newer marketplace and wellness footprint, and could help deepen engagement with younger, trend focused shoppers. How well these types of brands perform will matter for Ulta’s ability to defend share and protect margins as costs and competition rise.

Yet, while wellness launches feel encouraging, investors should still be alert to how rising store costs and wage inflation could eventually pressure margins and returns...

Ulta Beauty’s narrative projects $14.7 billion revenue and $1.4 billion earnings by 2029. This requires 5.8% yearly revenue growth and about a $0.2 billion earnings increase from $1.2 billion today.

Uncover how Ulta Beauty's forecasts yield a $681.50 fair value, a 51% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Ulta could reach about US$15.1 billion in revenue and US$1.5 billion in earnings, and they see wellness partnerships and marketplace expansion as proof that margin improvement and share gains are achievable, even though recent news like Being Frenshe’s rollout might ultimately push both the bullish and more cautious narratives to be revisited.

Explore 6 other fair value estimates on Ulta Beauty - why the stock might be worth as much as 51% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ulta Beauty research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Ulta Beauty research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ulta Beauty's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.